Bruce Steinberg, MD
Addiction Medicine · Encino, CANPI 1053431023
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 141 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,565 and has fallen 86.4% since, to $213 in 2025. Among addiction medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 141 payments — averaging $24.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$782
- Lundbeck LLC$554
- Johnson & Johnson$336
- Takeda Pharmaceuticals U.S.A., Inc.$264
- Otsuka America Pharmaceutical, Inc.$242
- Supernus Pharmaceuticals, Inc.$199
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,493100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,493 in reported general payments places this provider in the 90th percentile of 190 addiction medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lisdexamfetamine Dimesylate | 21 | $4,291 |
| Atomoxetine Hcl | 11 | $757 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $689 |
| Bupropion XlBupropion Hcl | 27 | $612 |
| Mirtazapine | 12 | $446 |
| Escitalopram Oxalate | 17 | $352 |
| Alprazolam | 18 | $117 |
| Clonazepam | 15 | $57 |
| Lamotrigine | 16 | $54 |
| Zolpidem Tartrate | 13 | $8 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Encino
- Tipu KhanVentura$262K
- Anthony AlbaneseMather$135K
- Matthew TorringtonCulver City$77K
- Kenneth StarrArroyo Grande$64K
- Drew PinskySouth Pasadena$60K
- Mark HonzelBeverly Hills$27K
- Bryan HylerVista$17K
- Abraham MalkinLos Angeles$12K
- Jonathan ReitmanBeverly Hills$11K
- Caleb LuskSan Pedro$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.